Overview

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Status:
Not yet recruiting

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab (DA-EPOCH-R) for patients with previously untreated aggressive B-cell lymphoid malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Cyclophosphamide
Doxorubicin
Etoposide
Liposomal doxorubicin
Loncastuximab tesirine
Prednisone
Rituximab
Vincristine